Angiotensin II (Ang II) stimulates vascular smooth muscle cell (VSMC) hypertrophy as a critical event in the development of vascular diseases such as atherosclerosis. Sirtuin (SIRT) 1, a nicotinamide adenine dinucleotide dependent deacetylase, has been demonstrated to exert protective effects in atherosclerosis by promoting endothelium-dependent vascular relaxation and reducing macrophage foam cell formation, but its role in VSMC hypertrophy remains unknown. In this study, we tried to investigate the effect of SIRT1 on Ang II-induced VSMC hypertrophy. Results showed that adenoviral-mediated over-expression of SIRT1 significantly inhibited Ang IIinduced VSMC hypertrophy, while knockdown of SIRT1 by RNAi resulted in an increased [ 3 H]-leucine incorporation of VSMC. Accordingly, nicotinamide adenine dinucleotide phosphate oxidase 1 (Nox1) expression induced by Ang II was inhibited by SIRT1 in VSMCs. SIRT1 activator resveratrol decreased, whereas endogenous SIRT1 inhibitor nicotinamide increased Nox1 expression in A7r5 VSMCs. Furthermore, transcription factor GATA-6 was involved in the down-regulation of Nox1 expression by SIRT1. These results provide new insight into SIRT1's anti-atherogenic properties by suppressing Ang II-induced VSMC hypertrophy.
Introduction
Angiotensin (Ang) II, the main effector peptide of the renin-angiotensin system, not only modulates vasomotor tone and blood pressure, but also is implicated in the development of various vascular diseases characterized by the accumulation of vascular smooth muscle cells (VSMCs), such as atherosclerosis, hypertension, and restenosis after balloon angioplasty [1] . VSMC hypertrophy, a hallmark of vascular diseases, is induced by Ang II in the absence of other growth factors [2] . Accumulating evidence indicated that Ang II mediates its hypertrophy effects at least in part through reactive oxygen species (ROS), the production of which it stimulates [3] [4] [5] [6] . In blood vessels, nicotinamide adenine dinucleotide (NAD) phosphate (NADPH) oxidases are the major sources of ROS.
NADPH oxidases are a family of enzyme complexes with each member or isoform being distinguished by the catalytic 'Nox' or 'Duox' subunit that it utilizes to generate superoxide and other downstream of ROS [7] . There are seven members of the NADPH oxidase family including Nox1-through 5-as well as Duox1-and 2-containing oxidases, in which three isoforms (Nox1, Nox4, and Nox5) were detected in VSMCs [3, [8] [9] [10] . Among them, Nox1 was reported to be the mediator of Ang II-induced superoxide formation in VSMCs [3] . Moreover, Nox1 itself was reported to be involved in prostaglandin F 2a (PGF 2a )-induced hypertrophy of VSMCs in culture [11] . SIRT1, the closest homology to yeast Sir2 protein (silent information regulator 2) in the human sirtuins, functions as a NAD þ dependent deacetylase, which has been implicated in the process of aging, metabolism, and tolerance to oxidative stress [12] . Emerging evidence suggested that SIRT1 functions as a metabolic sensor coupling energy and oxygen homeostasis to the growth and function of the vasculature [13] . Furthermore, SIRT1 has been demonstrated to be an anti-atherosclerosis factor through inhibiting oxidized low-density lipoprotein (oxLDL)-induced human umbilical vein endothelial cell apoptosis [14] , promoting endothelium-dependent vascular relaxation [15] , improving phagocytosis in peritoneal macrophages ( pMVs) [16] and reducing macrophage foam cell formation [17] .
Ang II has been well established to stimulate protein synthesis and induce cellular hypertrophy in VSMCs. It may also participate in the induction of pathological states associated with atherosclerosis [18, 19] . Despite recent advances in our understanding of the protective effects of SIRT1 in atherogenesis, no information is currently available regarding the effect of SIRT1 on VSMC hypertrophy. The aims of this study are, therefore, to investigate the effect of SIRT1 on Ang II-induced VSMC hypertrophy and to elucidate the molecular mechanism that may be responsible for the putative effect of SIRT1.
Materials and methods

Materials and reagents [
3 H]-leucine was purchased from Moravek Biochemicals (Brea, USA). Synthetic human Ang II, resveratrol (RV), nicotinamide (NAM) and anti-b-actin antibody were purchased from Sigma-Aldrich (St. Louis, USA). Anti-mSirt1 (mouse Sirt1) antibody was purchased from Millipore (Billerica, USA). hSIRT1 (human SIRT1) rabbit polyclonal antibody and anti-c-myc antibody were purchased from Santa Cruz Biotechnology Inc (Santa Cruz, USA). Antibodies against phospho-ERK1/2, ERK1/2 were purchased from Cell Signaling Technology (Beverly, USA).
Cell cultures
The A7r5 and A10 rat embryonic aortic VSMCs and 293A cell were obtained from the American Type Culture Collection (ATCC, Manassas, USA) and cultured in Dulbecco's modified Eagle's medium (DMEM) (Gibco Laboratories, Grand Island, USA) with 10% fetal bovine serum (FBS) (Gibco Laboratories) and antibiotics. Rat aortic VSMCs were isolated from the thoracic aorta of male Sprague-Dawley rats by enzymatic digestion, and then cultured in DMEM supplemented with 2 mmol/l L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin, and 10% FBS. VSMCs were kept at 378C in a humidified atmosphere with 5% CO 2 and were used until 80% confluent in the experiments at passages 3-5. The medium was changed before experiments.
Adenovirus generation and infection
The replication-defective adenoviral vectors expressing SIRT1 (Ad-SIRT1) or control green fluorescent protein (Ad-GFP), and adenovirus-mediated knockdown of SIRT1 (Ad-SIRT1 RNAi) or control vector (Ad-U6) were generated by using the Ad Easy Vector kit (Quantum Biotechnologies, Montreal, Canada) as described before [14, 16] . VSMCs were infected for 12 or 24 h with the above adenovirus at a multiplicity of infection (MOI) of 100, washed, and incubated in the serum-free medium without virus for 24 or 48 h.
Western blot analysis
Cellular proteins were extracted with Radio Immuno Precipitation Assay (RIPA) buffer [25 mmol/l Tris -HCl ( pH 7.6), 150 mmol/l NaCl, 1% NP-40, 1% sodium deoxycholate, and 0.1% sodium dodecyl sulfate (SDS)]. After complete homogenization on ice, samples were centrifuged at 48C, 12000 g for 30 min to precipitate the cell debris. The supernatants were transferred into fresh tubes and the protein concentrations were determined by BCA method. Proteins were fractionated by 10% SDS-PAGE and electro-transferred onto a PVDF membrane (Millipore, Bedford, USA). The membranes were blocked with Tris-buffered saline containing 5% non-fat milk, probed with primary antibody and then HRP-conjugated secondary antibody at 48C overnight. The blots were developed by using the ECL system (Pierce, Chicago, USA). Band intensities were quantified by densitometry. The results were normalized to b-actin as an internal control.
RT-PCR analysis
Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, USA) according to the manufacturer's protocol. Two micrograms of total RNA was used to synthesize firststrand with cDNA M-MuLV reverse transcriptase (New England Biolabs, Beverly, USA) using random primers. RT-PCR was used to analyze Nox1, Nox4, and b-actin mRNA levels in cells. Primers used in PCR are listed as follows: human SIRT1 sense 5
[ 3 H]-leucine incorporation assay VSMCs were plated onto 12-well plates at a density of 50,000 cells per well, and infected with adenovirus overnight, then serum starved for 48 h. After that, cells were incubated with [ 3 H]-leucine (2 mCi per well) in the presence or absence of 100 nmol/l Ang II for 24 h. At the end of the experiment, the cells were washed with cold PBS, scraped off the well, and then treated with 10% trichloroacetic acid at 48C for 60 min. The precipitates were dissolved in NaOH (0.4 mol/l) and subsequently counted with a liquid scintillation counter.
Plasmids
The plasmid containing the coding sequence of human SIRT1 (pcDNA3.1-SIRT1) was a kind gift from Prof. F. Ishikawa (Kyoto University, Kyoto, Japan). The plasmid containing coding sequence of full-length mouse GATA-6 (pCMVTag3b-GATA-6) was kindly provided by Prof. Patricia A. Mericko (University of Pennsylvania, USA).
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Co-immunoprecipitation assay 293A cells were cotransfected with the plasmids encoding myc-tagged GATA-6 and SIRT1. Then the whole-cell lysates were preincubated with 1.0 mg non-immune rabbit IgG and 20 ml of protein A-Sepharose beads (Millipore) at 48C for 3 h and centrifuged. Cleared lysates (1 mg) were immunoprecipitated with the anti-hSIRT1 or anti-c-myc (for c-myc-GATA-6) antibodies at 48C for 1 h and then incubated with protein A-Sepharose beads at 48C overnight. The immunoprecipitated proteins were washed six times with lysis buffer and resuspended in the electrophoresis sample buffer. Samples of immunoprecipitated or total proteins (20-30 mg) were analyzed by western blot using anti-c-myc or anti-hSIRT1 primary antibodies.
Statistical analysis
Data are presented as mean + SEM. Statistical analyses between groups were done by Student's t-test or one-way ANOVA followed by a Bonferroni post hoc test. A probability value of ,0.05 was considered significant. Fig. 1(A) ]. To further investigate the role of SIRT1 in VSMC hypertrophy, we used adenovirus-mediated RNAi of SIRT1, which had been proved efficiently in rat VSMCs. We found that knockdown of SIRT1 by RNAi in rat VSMCs resulted in an increased [ 3 H]-leucine incorporation of VSMCs under both basal and Ang II-induced conditions, which suggested that SIRT1 might act as a modulator of VSMC protein synthesis [ Fig. 1(B) ]. Fig. 2(A, B) ]. Over-expression of SIRT1 significantly decreased Nox1 mRNA induced by Ang II [ Fig. 2(C) ]. As Nox4 was expressed abundant and stood for NADPH oxidase activity largely under resting conditions in VSMCs [3, 8] , we checked whether SIRT1 regulated Nox4 mRNA expression. Ang II decreased Nox4 mRNA in a previous report [3] , and over-expression of SIRT1 had no effect on Nox4 mRNA level [ Fig. 2(D) ]. Thus, down-regulation of Nox1 but not Nox4 mRNA by SIRT1 was involved in its inhibitory effect on Ang II-induced VSMC hypertrophy. Of note, SIRT1 activator resveratrol decreased Nox1 mRNA level at a dose of 100 mM [ Fig. 2(E) ], whereas endogenous SIRT1 inhibitor NAM increased Nox1 expression in A7r5 VSMCs [ Fig. 2(F) ].
Results
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Transcription factor GATA-6 is involved in the down-regulation of Nox1 expression by SIRT1 Besides the activity regulation, the transcriptional regulation of Nox1 appears to be particularly important [25] . Transcription factor GATA-6 is implicated in the regulation 
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of Nox1 transcription by direct binding to the Nox1 proximal promoter [26] . To elucidate the possible mechanism of Nox1 down-regulated by SIRT1, we co-transfected expression plasmids encoding GATA-6 and SIRT1 in A10
VSMCs and checked out the effect of SIRT1 on the transcriptional regulation of Nox1 by GATA-6. As shown in Fig. 3A , Nox1 mRNA expression was increased after GATA-6 plasmid transfection, but it was significantly 
attenuated when co-transfecting with SIRT1 plasmid, which suggested that SIRT1 could down-regulate Nox1 mRNA expression through GATA-6. Furthermore, we performed immunoprecipitation experiments to investigate whether SIRT1 could interact with GATA-6 and found that SIRT1 co-immunoprecipitated with c-myc tagged GATA-6 as indicated, and vice versa [ Fig. 3(B) ], which may lead to the decreased Nox1 expression by SIRT1.
SIRT1 suppresses Ang II-induced ERK1/2 phosphorylation in VSMCs
Previous studies have shown that activation of GATA-6 by Ang II is mitogen-activated protein kinase-extracellular signal-regulated kinase (ERK)1/2 dependent [27] . To find out whether ERK/MAPKs signaling pathway was involved in the inhibitory effect of SIRT1 on Ang II-induced VSMC hypertrophy, we detected ERK1/2 phosphorylation by western blot analysis. As expected, Ang II significantly induced ERK1/2 phosphorylation, especially at 5 min after Ang II stimulation [ Fig. 4(A) ]. And phosphorylation of ERK1/2 was significantly inhibited by SIRT1 overexpression [ Fig. 4(B) ].
Discussion
Accumulating evidence has implied Nox1 to be a critical modulator of VSMC hypertrophy. In a rat VSMC derived cell line A7r5, depletion of Nox1 mRNA by ribozymes significantly reduced the increased protein synthesis induced by PGF 2a [11] . Also, smooth muscle-specific Nox1 overexpression potentiated Ang II-induced vascular smooth muscle hypertrophy, and this potentiation of vascular hypertrophy was due to increased ROS formation [28] . While NOX1-deficient mice showed a marked reduction in Ang II-induced media hypertrophy [29] . In the present study, we found that over-expression of SIRT1 suppressed Ang II-induced VSMC hypertrophy at least in part via down-regulating Nox1 mRNA expression. Alternatively, SIRT1-mediated inhibition of Ang II-induced VSMC hypertrophy might be through decreasing ROS originated from Nox1 induced by Ang II. The activation state and protein expression of Nox/Duox enzymes, plus their regulatory subunits determine the SIRT1 inhibits angiotensin II-induced VSMC hypertrophy maximum capacity of the cell to generate ROS [25] . Rather, the transcriptional regulation of Nox1 appears to be particularly important in the modulation of its activity [3, 10, 30] . GATA-6, a member of the GATA family of zinc finger transcription factors, is the predominant one expressed in vascular SMCs and maintains the differentiated VSMC phenotype by inhibiting SMC proliferation [31, 32] . GATA-6 acts to up-regulate Nox1 in colon epithelial cells by direct binding to a proximal site within the Nox1 promoter [26] . Moreover, GATA-6 is stimulated by Ang II and regulates genes promoting synthetic functions in VSMCs [27, 33] , which suggests that GATA-6 activation plays a role in VSMC hypertrophy induced by Ang II. Thus, our findings that SIRT1 inhibited GATA-6-induced Nox1 expression provide the possible mechanism for SIRT1 suppressing Ang II-induced VSMC hypertrophy. In the future, it will be interesting to determine whether SIRT1 can deacetylate GATA-6 to mediate the inhibitory effects, for SIRT1 functions through deacetylating a variety of substrates, including histones, transcription factors and coregulators [12] .
In VSMCs, p38MAPK, Akt and ERK1/2 signaling pathways activated by Ang II result in increased protein synthesis [1, 34] . In the present study, we found that phosphorylation of ERK1/2 was significantly inhibited by SIRT1 over-expression in VSMCs, suggesting that suppressing this signaling pathway also contributes to SIRT1's anti-Ang II-induced VSMC hypertrophy effect. This result was in accordance with a previous study that SIRT1 activator resveratrol suppressed Ang II-induced AT1R expression and inhibited ERK1/2 phosphorylation in VSMCs, which contributed to the inhibition of Ang II-induced hypertension by resveratrol [35] . Nevertheless, we did not find the substantial change of AT1R protein expression by SIRT1 in Ang II-induced VSMCs (data not shown), which suggested that the down-regulation of Nox1 expression might be more important to mediate the suppressive effect of SIRT1 on Ang II-induced VSMC hypertrophy.
SIRT1 has been shown to control stress resistance by regulating the FOXO transcription factor FOXO3 and the tumor suppressor p53 [36 -38] . It is also up-regulated in response to different stimuli such as oxidized oxLDL, hydrogen peroxide (H 2 O 2 ) [14] , and TNF-alpha in vascular cells [39] . In this study, we also found that hypertrophic agent Ang II treatment increased SIRT1 expression in VSMCs (data not shown), which seemed to be a compensative effect in protecting against Ang II-induced VSMC hypertrophy. Consistent with this notion, VSMCs infected with adenoviral SIRT1 attenuated Ang II-induced VSMC hypertrophy in vitro. We recently found that NF-kB, the mediator of the proinflammatory action of Ang II [40, 41] , mediated TNF-alpha-induced SIRT1 expression in VSMCs [39] . Hence, we guess that NF-kB may also mediate Ang II-induced SIRT1 expression in VSMCs, which needs to be verified in the future study.
In conclusion, our results showed that SIRT1 significantly inhibited Ang II-induced VSMC hypertrophy. And suppression of Nox1 mRNA at least in part contributed to the inhibitory effect of SIRT1 on Ang II-induced VSMC hypertrophy. Our work provides new insight into SIRT1's atheroprotective effects, and implicates SIRT1 as a potential target for the intervention of VSMC hypertrophyassociated vascular diseases.
